Abstract
Currently, substitution of clotting factors is the most commonly used option for patients affected by haemophilia. Factors are well established, but expensive. This research aims to explore the cost of the most widely used clotting factors in Austria and compares these with projected costs of gene therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
